RLYB
Company Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 858,000 | 636,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.98M) | (57.77M) | (74.56M) | (66.65M) | (47.01M) | (26.45M) | (17.63M) |
| EPS | -1.59 | -10.64 | -14.72 | -16.72 | -11.68 | -9.52 | -4.40 |
| Free Cash Flow | (29.81M) | (49.28M) | (60.28M) | (57.34M) | (45.87M) | (22.18M) | (15.21M) |
| FCF / Share | -5.30 | -9.05 | -11.92 | -14.41 | -11.42 | -7.98 | -5.47 |
| Operating CF | (29.81M) | (49.28M) | (60.27M) | (57.28M) | (45.53M) | (22.04M) | (15.03M) |
| Total Assets | 62.26M | 68.11M | 115.62M | 180.44M | 182.19M | 141.86M | 21.61M |
| Total Debt | 176,000 | 154,000 | 392,000 | 555,000 | 0 | 0 | 0 |
| Cash & Equiv | 31.37M | 13.90M | 24.49M | 56.96M | 175.33M | 140.23M | 19.46M |
| Book Value | 57.96M | 61.65M | 106.18M | 169.32M | 175.60M | 136.00M | 16.86M |
| Return on Equity | -0.15 | -0.94 | -0.70 | -0.39 | -0.27 | -0.19 | -1.05 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 212,000 | 222,000 | 212,000 | 212,000 | 212,000 | 38,000 | 299,000 | 299,000 | 0 | 228,000 | 0 | 0 |
| Net Income | (8.28M) | (5.85M) | 16.02M | (9.70M) | (9.44M) | (11.04M) | (11.47M) | (16.24M) | (19.03M) | (20.24M) | (18.37M) | (18.63M) |
| EPS | -1.46 | -1.11 | 2.84 | -1.76 | -1.68 | -2.00 | -2.08 | -2.96 | -3.76 | -4.00 | -3.60 | -3.68 |
| Free Cash Flow | (7.98M) | (4.68M) | (6.55M) | (8.38M) | (10.21M) | (9.86M) | (13.54M) | (10.42M) | (15.46M) | (11.66M) | (16.47M) | (13.38M) |
| FCF / Share | -1.40 | -0.89 | -1.16 | -1.49 | -1.82 | -1.77 | -2.43 | -1.89 | -3.03 | -2.29 | -3.25 | -2.65 |
| Operating CF | (7.98M) | (4.68M) | (6.55M) | (8.38M) | (10.21M) | (9.86M) | (13.54M) | (10.42M) | (15.46M) | (11.64M) | (16.47M) | (13.38M) |
| Total Assets | 54.47M | 62.26M | 67.66M | 51.00M | 57.98M | 68.11M | 79.01M | 92.43M | 99.36M | 115.62M | 133.19M | 147.58M |
| Total Debt | 154,000 | 176,000 | 198,000 | 58,000 | 116,000 | 154,000 | 230,000 | 284,000 | 339,000 | 392,000 | 428,000 | 479,000 |
| Cash & Equiv | 41.30M | 31.37M | 32.12M | 9.45M | 14.78M | 13.90M | 25.32M | 16.67M | 19.30M | 24.49M | 19.16M | 32.56M |
| Book Value | 50.28M | 57.96M | 63.03M | 45.96M | 54.07M | 61.65M | 70.82M | 80.02M | 89.16M | 106.18M | 123.58M | 139.26M |
| Return on Equity | -0.16 | -0.10 | 0.25 | -0.21 | -0.17 | -0.18 | -0.16 | -0.20 | -0.21 | -0.19 | -0.15 | -0.13 |
